Press coverage about Immunomedics (NASDAQ:IMMU) has been trending somewhat positive on Saturday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.11 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.92347152816 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern’s scoring:
Immunomedics (NASDAQ IMMU) traded up $0.26 during trading on Friday, hitting $16.51. The company’s stock had a trading volume of 2,267,227 shares, compared to its average volume of 3,880,000. The company has a market cap of $2,510.00, a price-to-earnings ratio of -7.37 and a beta of 1.48. Immunomedics has a twelve month low of $3.83 and a twelve month high of $17.24. The company has a current ratio of 0.74, a quick ratio of 0.74 and a debt-to-equity ratio of -0.29.
IMMU has been the subject of several research reports. Jefferies Group increased their target price on Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Zacks Investment Research raised Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research report on Wednesday, October 4th. BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine lowered Immunomedics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $15.33.
In other news, Director Brian A. Markison sold 8,390 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $11.89, for a total value of $99,757.10. Following the transaction, the director now directly owns 99,178 shares in the company, valued at approximately $1,179,226.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Venbio Select Advisor Llc purchased 1,150,000 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The disclosure for this purchase can be found here. 6.60% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/13/immunomedics-immu-receiving-somewhat-positive-news-coverage-accern-reports.html.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.